To include your compound in the COVID-19 Resource Center, submit it here.

FDA accepts NDA for Lutathera

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) said FDA accepted for review a resubmitted NDA

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE